# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Project will utilize an integrated approach to develop an in vitro alternative to inhalation toxicology studiesCharles River La...
Mizuho analyst Ann Hynes initiates coverage on Charles River (NYSE:CRL) with a Neutral rating and announces Price Target of ...
Goldman Sachs analyst Matthew Sykes initiates coverage on Charles River (NYSE:CRL) with a Buy rating and announces Price Tar...
Fast Track and Modular frameworks facilitate product development continuity via seamless process transfer to the Company's ...
TD Cowen analyst Charles Rhyee maintains Charles River (NYSE:CRL) with a Hold and lowers the price target from $260 to $228.
Baird analyst Eric Coldwell maintains Charles River (NYSE:CRL) with a Outperform and lowers the price target from $282 to $270.